CompletedPhase 1

Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

South Korea3 participantsStarted 2023-12-06

Plain-language summary

The purpose of this clinical trial was to evaluate the safety and tolerability for 12 weeks after one dose of TRTP-101 in adults with atrophic scars.

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Male or Female aged greater than 19 years
✓. Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose

✕. History of cell therapy
✕. Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation
✕. Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting
✕. Positive for virus infection
✕. Use of Anticoagulant therapy or NSAIDs
✕. Thrombocytopenia or other coagulation disorder
✕. History of keloid scars
✕. Infectious disease or other dermatitis in the area of the atrophic scar

Number of Participants with Dose Limiting Toxicity

Timeframe: within 4 weeks

NCT IDNCT06210919

SponsorCellinCells

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-12-10